MeiraGTx Stock Gains 5% on Narrower FY25 Loss and FDA Breakthrough Designation

MeiraGTx Holdings reported a narrower loss of $114.2 million for FY25, a decline from $147.8 million last year. The company's shares rose 5% after the announcement and FDA's Breakthrough Designation for AAV2-hAQP1 treatment for late xerostomia caused by radiotherapy for cancers of the upper aerodigestive tract.